A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide

被引：0
作者：
Yamaoka, Keiko [1 ]
Nagashima, Shuichi [1 ]
Okada, Nobukazu [1 ]
Sawayama, Nagisa [1 ]
Saito, Shinsuke [1 ]
Takahashi, Manabu [1 ]
Okada, Kenta [1 ]
Endo, Kazuhiro [2 ]
Koizumi, Masaru [2 ]
Sasanuma, Hideki [2 ]
Ebihara, Ken [1 ]
Kasajima, Atsuko [4 ,5 ]
Fukushima, Noriyoshi [3 ]
Sata, Naohiro [2 ]
Ishibashi, Shun [1 ]
机构：
[1] Jichi Med Univ, Dept Med, Div Endocrinol & Metab, 3311-1 Yakushiji, Shimotsuke, Tochigi, Japan
[2] Jichi Med Univ, Dept Surg, Shimotsuke, Tochigi, Japan
[3] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi, Japan
[4] Tohoku Univ, Dept Pathol, Grad Sch Med, Sendai, Miyagi, Japan
[5] Tech Univ Munich, Dept Pathol, Munich, Germany
来源：
CLINICAL CASE REPORTS | 2021年 / 9卷 / 05期
关键词：
hypoglycemia; insulinoma; lanreotide; octrcotidc; somatostatin analog; SOMATOSTATIN ANALOG; THERAPY; AUTOGEL;
D O I：
10.1002/ccr3.4118
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Long-acting somatostatin analogs, including lanreotide slow release (LAN-SR) and octreotide long-acting release (OCT-LAR), can improve hypoglycemia in insulinoma. LAN-SR may be more beneficial in some patients with insulinoma than OCT-LAR.
引用
收藏
页数：5
相关论文
共 19 条
  • [1] Prolonged life-threatening hypoglycaemia following dose escalation of octreotide LAR in a patient with malignant polysecreting pancreatic neuroendocrine tumour
    Abell, Sally K.
    Teng, Jessie
    Dowling, Anthony
    Hofman, Michael S.
    MacIsaac, Richard J.
    Sachithanandan, Nirupa
    [J]. ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, 2015,
  • [2] A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
    Andries, Magdalene
    Glintborg, Dorte
    Kvistborg, Annette
    Hagen, Claus
    Andersen, Marianne
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 68 (03) : 473 - 480
  • [3] Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439
  • [4] Long-acting octreotide and prolonged-release lanreotide formulations have different pharmacokinetic profiles
    Astruc, B
    Marbach, P
    Bouterfa, H
    Denot, C
    Safari, M
    Vitaliti, A
    Sheppard, M
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (07) : 836 - 844
  • [5] Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline
    Cryer, Philip E.
    Axelrod, Lloyd
    Grossman, Ashley B.
    Heller, Simon R.
    Montori, Victor M.
    Seaquist, Elizabeth R.
    Service, F. John
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2009, 94 (03) : 709 - 728
  • [6] OCTREOTIDE EXACERBATED FASTING HYPOGLYCEMIA IN A PATIENT WITH A PROINSULINOMA - THE GLUCOSTATIC IMPORTANCE OF PANCREATIC GLUCAGON
    GAMA, R
    MARKS, V
    WRIGHT, J
    TEALE, JD
    [J]. CLINICAL ENDOCRINOLOGY, 1995, 43 (01) : 117 - 120
  • [7] Diazoxide treatment for insulinoma: a national UK survey
    Gill, GV
    Rauf, O
    MacFarlane, IA
    [J]. POSTGRADUATE MEDICAL JOURNAL, 1997, 73 (864) : 640 - 641
  • [8] Effective Therapy of Insulinoma by Using Long-Acting Somatostatin Analogue. A Case Report and Literature Review
    Jawiarczyk, A.
    Bolanowski, M.
    Syrycka, J.
    Bednarek-Tupikowska, G.
    Kaluzny, M.
    Kolodziejczyk, A.
    Domoslawski, P.
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2012, 120 (02) : 68 - 72
  • [9] The diagnosis and medical management of advanced neuroendocrine tumors
    Kaltsas, GA
    Besser, GM
    Grossman, AB
    [J]. ENDOCRINE REVIEWS, 2004, 25 (03) : 458 - 511
  • [10] PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF A LONG-ACTING FORMULATION OF THE NEW SOMATOSTATIN ANALOG, LANREOTIDE, IN NORMAL HEALTHY-VOLUNTEERS
    KUHN, JM
    LEGRAND, A
    RUIZ, JM
    OBACH, R
    DERONZAN, J
    THOMAS, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (03) : 213 - 219
12